Current and future use of angiotensin II receptor blockers in patients with COVID-19
No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within clinical trials. Patients who have been taking...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | No scientific evidence for the negative influence of angiotensin II receptor blockers onto COVID-19 clinical course has been identified so far. Prescribing angiotensin II receptor blockers as COVID-19 pathogenetic therapy could only be considered within clinical trials. Patients who have been taking angiotensin II receptor blockers for approved indications should continue to do so. |
|---|---|
| Item Description: | 2588-0519 2618-8473 10.37489/2588-0519-2020-S4-28-31 |